Cathie "Wood's latest investment moves for 2026 are concentrated on early-stage biotech companies, while gradually reducing exposure to firms in the consumer technology, diagnostics, and space technology sectors. The asset management firm ARK Invest, founded and led by "Wood," has significantly increased its allocation to gene editing and genomics targets, with the primary purchase being the US biotech company Beam Therapeutics (BEAM.US). As a pioneer in base editing technology, Beam is utilizing this technology to develop precision genetic medicines to correct disease-causing mutations. It was disclosed that across the flagship ARK Innovation ETF (ARKK.US) and the ARK Genomic Revolution ETF (ARKG.US), ARK cumulatively added over 195,000 shares of Beam Therapeutics stock, with a holding value of approximately $5.4 billion, marking its most aggressive bet recently. Continuing the pace of last week's operations, the investment firm further increased its holding in Intellia Therapeutics (NTLA.US) by about 236,000 shares—this medical company, which uses CRISPR technology to repair disease-causing genes, aligns perfectly with its strategic direction. To further underscore ARK's long-term preference for genomic discovery and precision medicine tools, the firm simultaneously purchased over 423,000 shares of sequencing technology provider Pacific Biosciences of California (PACB.US). ARK invested over $3 million to acquire 101,000 shares of Twist Bioscience (TWST.US), a company focused on the research, development, and production of synthetic DNA, with products widely used in drug development, data storage, and biological research. At the same time, ARK also increased its holding in Personalis (PSNL.US) by 88,000 shares—this company's ultra-deep DNA sequencing technology can be precisely applied to early cancer detection and minimal residual disease monitoring. In its non-medical sector allocations, the ARK Autonomous Technology & Robotics ETF (ARKQ.US) continued its buying activity, adding 61,874 shares of Kodiak AI (KDK.US). Concurrently, the ARK Genomic Revolution ETF (ARKG.US) also expanded its investment exposure to the precision medicine data platform Tempus AI (TEM.US). On the selling side, ARK is systematically adjusting its holdings structure in certain healthcare and technology sectors. Specifically, the ARK Genomic Revolution ETF (ARKG.US) reduced its position in the biotech company Ionis Pharmaceuticals (IONS.US), which focuses on RNA-targeted therapies, by 26,645 shares, while also scaling back its holdings in genetic testing company Natera (NTRA.US) and Guardant Health (GH.US), which specializes in blood-based genomic cancer testing. The flagship ARK Innovation ETF completed structural portfolio adjustments: it sold over 72,000 shares of the streaming and advertising technology platform Roku (ROKU.US) and simultaneously reduced its holding in Canadian e-commerce software provider Shopify (SHOP.US) by more than 29,000 shares. Meanwhile, the ARK Autonomous Technology & Robotics ETF (ARKQ.US) executed a precise reduction in its position in space launch and satellite systems supplier Rocket Lab (RKLB.US). Observing the performance of Cathie Wood's ARK investment funds in 2025—despite selling over 633,000 shares of Tesla (TSLA.US) stock, the company still firmly holds the top position as its largest holding, and the funds overall significantly outperformed major US benchmark indices by a wide margin.